AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37795393 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (19 Gy in 1 fraction)
Number of subjects: 0
Study 37795393 — intervention group
Group type: COMPARATOR
Intervention: EBRT (8 Gy in 1 fraction)
Number of subjects: 0
Study 37795521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine prescribed at baseline.
Number of subjects: 486
Study 37795521 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk of acquiring HIV (due to condomless sex, frequent sex, and STIs).
Number of subjects: 486
Study 37795589 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted transcranial Doppler (raTCD)
Number of subjects: 154
Study 37795589 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 154
Study 37795617 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive endotyping with disclosure of results to the invasive cardiologist
Number of subjects: 231
Study 37795617 — intervention group
Group type: COMPARATOR
Intervention: Control group with nondisclosure of results
Number of subjects: 231
Study 37795682 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-hour indoor event in a nightclub at full capacity, with no masking, prior SARS-CoV-2 test result, or social distancing required.
Number of subjects: 1216
Study 37795682 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-attendees) with no exposure to the indoor event.
Number of subjects: 1216
Study 37795682 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubbing event exposure (attendees).
Number of subjects: 1216
Study 37795783 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (including CBT, behavioral interventions, integrative therapies, humanist therapies, and other psychologically oriented interventions)
Number of subjects: 3992
Study 37795783 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 3992
Study 37795883 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Insulin Delivery System
Number of subjects: 0
Study 37795976 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B
Number of subjects: 160
Study 37795976 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59
Number of subjects: 160
Study 37795976 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with AS01B
Number of subjects: 160
Study 37795976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 37796016 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplantation (aFMT)
Number of subjects: 82
Study 37796016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 37796017 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 44
Study 37796114 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP
Number of subjects: 264
Study 37796114 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF
Number of subjects: 264
Study 37796117 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60
Study 37796117 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (i-PRF)
Number of subjects: 60
Study 37796117 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with no injections (Control group)
Number of subjects: 60
Study 37796398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 3 mg QD 3/1 (n=7)
Number of subjects: 20
Study 37796398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg QD 3/1 (n=7)
Number of subjects: 20
Study 37796398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg RP2D (n=6)
Number of subjects: 20
Study 37796417 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR on interfering medications
Number of subjects: 715
Study 37796417 — intervention group
Group type: COMPARATOR
Intervention: ARR off interfering medications
Number of subjects: 715
Study 37796417 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR on interfering medications (threshold 10 pg/μIU)
Number of subjects: 715
Study 37796417 — intervention group
Group type: COMPARATOR
Intervention: ARR off interfering medications (threshold 10 pg/μIU)
Number of subjects: 715
Study 37796513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab, 200 mg intravenously every 3 weeks
Number of subjects: 674
Study 37796513 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib tosylate, 400 mg orally twice daily
Number of subjects: 674
Study 37796513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 674
Study 37796513 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 674
Study 37796540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBN
Number of subjects: 0
Study 37796540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 10 mg CBD
Number of subjects: 0
Study 37796540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 20 mg CBD
Number of subjects: 0
Study 37796540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 100 mg CBD
Number of subjects: 0
Study 37796540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37796597 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parent training (PT) program
Number of subjects: 0
Study 37796657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0
Study 37796657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 0
Study 37796657 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37796764 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (ESC)
Number of subjects: 178
Study 37796764 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) + aripiprazole (ARI)
Number of subjects: 178
Study 37796764 — intervention group
Group type: COMPARATOR
Intervention: escitalopram (ESC) only
Number of subjects: 178
Study 37796776 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB participants (OAB-2)
Number of subjects: 0
Study 37796776 — intervention group
Group type: COMPARATOR
Intervention: Control participants (CON-1)
Number of subjects: 0
Study 37796776 — intervention group
Group type: COMPARATOR
Intervention: OAB participants (OAB-1)
Number of subjects: 0
Study 37796784 — intervention group
Group type: EXPERIMENTAL
Intervention: LDART (Let's Do Addiction Recovery Together!) intervention used every night for a month
Number of subjects: 30
Study 37796784 — intervention group
Group type: EXPERIMENTAL
Intervention: LDART (Let's Do Addiction Recovery Together!) intervention
Number of subjects: 30
Study 37796870 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial induction
Number of subjects: 84
Study 37796870 — intervention group
Group type: COMPARATOR
Intervention: Simulation of myofascial induction
Number of subjects: 84
Study 37797219 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Oil
Number of subjects: 0
Study 37797219 — intervention group
Group type: COMPARATOR
Intervention: Breast Milk
Number of subjects: 0
Study 37797293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 360 mg
Number of subjects: 462
Study 37797293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 180 mg
Number of subjects: 462
Study 37797293 — intervention group
Group type: COMPARATOR
Intervention: Placebo [withdrawal]
Number of subjects: 462
Study 37797310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 144
Study 37797310 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 144
Study 37797387 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (Cap) 2000 mg/m² day 1-14 q3w for 6 cycles plus ibandronate (Ib) 50 mg p.o. daily or 6 mg intravenous q4w for 2 years
Number of subjects: 1358
Study 37797387 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate (Ib) alone for 2 years
Number of subjects: 1358
Study 37797387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap+Ib
Number of subjects: 1358
Study 37797404 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma citrulline concentration among septic patients
Number of subjects: 109
Study 37797404 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma LPS concentration and activity
Number of subjects: 109
Study 37797404 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of LPS
Number of subjects: 109
Study 37797547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic distal perfusion cannulation (PDPC)
Number of subjects: 479
Study 37797547 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic distal perfusion cannulation (no-PDPC)
Number of subjects: 479
Study 37797632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg and 10 mg/kg every 2 weeks (dose escalation phase)
Number of subjects: 240
Study 37797632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg and a fixed dose of 450 mg every 2 weeks (dose expansion phase)
Number of subjects: 240
Study 37797632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg every 2 weeks (phase 2)
Number of subjects: 240
Study 37797633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of cancer predisposing variants (641 participants, 5.1%)
Number of subjects: 12469
Study 37797633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of cancer predisposing variants
Number of subjects: 12469
Study 37797633 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of cancer predisposing variants
Number of subjects: 12469
Study 37797733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa (BA) with concurrent chemoradiotherapy (cCRT) followed by BA
Number of subjects: 153
Study 37797733 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concurrent chemoradiotherapy (cCRT) followed by durvalumab
Number of subjects: 153
Study 37797734 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 146
Study 37797734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 37797893 — intervention group
Group type: EXPERIMENTAL
Intervention: Leniolisib
Number of subjects: 37
Study 37797965 — intervention group
Group type: EXPERIMENTAL
Intervention: Research participation (exposed group)
Number of subjects: 1495
Study 37798029 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal achievement theory-based physical activity promotion programme (16-week, face-to-face and e-health blended)
Number of subjects: 114
Study 37798029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 37798422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment for carriers of novel HNF1A variants
Number of subjects: 615
Study 37798422 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional investigations of HNF1A variants
Number of subjects: 615
Study 37798422 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic sequencing for HNF1A variants
Number of subjects: 615
Study 37798422 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of HNF1A variants
Number of subjects: 615
Study 37798422 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence estimation of HNF1A-MODY
Number of subjects: 615
Study 37798468 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin 1200 mg three times daily for up to 21 days
Number of subjects: 279
Study 37798538 — intervention group
Group type: EXPERIMENTAL
Intervention: M8891 (a selective and reversible inhibitor of methionine aminopeptidase 2)
Number of subjects: 0
Study 37798538 — intervention group
Group type: EXPERIMENTAL
Intervention: M8891
Number of subjects: 0
Study 37798628 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol cardioplegia (CC)
Number of subjects: 226
Study 37798628 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (BC)
Number of subjects: 226
Study 37798642 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback system
Number of subjects: 30
Study 37798642 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 30
Study 37798650 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-adMSC therapy (5 intravenous infusions of 2 × 10^6 cells)
Number of subjects: 10
Study 37798658 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifetime (HL) health coaching program delivered electronically over eight weeks
Number of subjects: 122
Study 37798658 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifetime (HL) health coaching program for individuals with high blood pressure
Number of subjects: 122
Study 37798658 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 37798671 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetapir PET imaging
Number of subjects: 237
Study 37798671 — intervention group
Group type: COMPARATOR
Intervention: Cognitive impairment
Number of subjects: 237
Study 37798696 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized infant feeding support sessions delivered by a local professional lactation specialist, five sessions from pregnancy until three months postpartum.
Number of subjects: 20
Study 37798696 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized infant feeding support sessions
Number of subjects: 20
Study 37798696 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person sessions in a clinic setting
Number of subjects: 20
Study 37798696 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized professional infant feeding support sessions
Number of subjects: 20
Study 37798723 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi vaccine candidate genes (pd, pe, pilA) and Mcat gene (uspA2)
Number of subjects: 123
Study 37798723 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi vaccine candidate genes (pd, pilA)
Number of subjects: 123
Study 37798723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mcat gene (uspA2)
Number of subjects: 123
Study 37798756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia therapy along with conventional physical therapy (hot pack, strengthening, stretching)
Number of subjects: 52
Study 37798756 — intervention group
Group type: COMPARATOR
Intervention: Fascial manipulation treatment with conventional physical therapy
Number of subjects: 52
Study 37798801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg for 5 days)
Number of subjects: 60
Study 37798801 — intervention group
Group type: COMPARATOR
Intervention: Colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Number of subjects: 60
Study 37798808 — intervention group
Group type: EXPERIMENTAL
Intervention: CFT + AAR (after-action review)
Number of subjects: 0
Study 37798808 — intervention group
Group type: COMPARATOR
Intervention: CFT as usual (standard implementation)
Number of subjects: 0
Study 37798860 — intervention group
Group type: EXPERIMENTAL
Intervention: Explorer Baby early intervention program
Number of subjects: 51
Study 37798860 — intervention group
Group type: COMPARATOR
Intervention: Active control neurodevelopmental therapy (NDT)
Number of subjects: 51
Study 37798863 — intervention group
Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness in T2D individuals
Number of subjects: 122
Study 37798863 — intervention group
Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness decline rate
Number of subjects: 122
Study 37798863 — intervention group
Group type: COMPARATOR
Intervention: GCL + IPL thickness in ETDRS grade 20
Number of subjects: 122
Study 37798863 — intervention group
Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness in ETDRS grades 35 and 43-47
Number of subjects: 122
Study 37798863 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between GCL + IPL thinning and retinal capillary non-perfusion
Number of subjects: 122
Study 37799162 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention and control (IPC) intervention developed based on Phase 1 results and systematic literature review.
Number of subjects: 0
Study 37799162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap analysis conducted in Phase 1 to explore IPC practices among healthcare workers.
Number of subjects: 0
Study 37799526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent teaching unit based on the use of activity wristbands and behavior modification strategies
Number of subjects: 175
Study 37799526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 175
Study 37799613 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95
Study 37799613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 37799613 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg for 6 additional cycles during Extension Period)
Number of subjects: 95
Study 37799613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during First Period)
Number of subjects: 95
Study 37799724 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron-adapted vaccine
Number of subjects: 0
Study 37799724 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 0
Study 37799965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 37799965 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 37800112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with moderate-intensity rosuvastatin (RE 10) and ezetimibe (10 mg)
Number of subjects: 0
Study 37800112 — intervention group
Group type: COMPARATOR
Intervention: High-intensity rosuvastatin (R20)
Number of subjects: 0
Study 37800194 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Reinforcement Therapy (CRT)
Number of subjects: 103
Study 37800194 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 103
Study 37800325 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography myocardial blood flow (MBF) measurement using technetium-99m-tetrofosmin
Number of subjects: 175
Study 37800343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water pack application (80°C, applied at 3, 6, 9, and 12 hours postoperatively for 30 minutes each time)
Number of subjects: 121
Study 37800343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water pack application
Number of subjects: 121
Study 37800343 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized enhanced recovery protocols)
Number of subjects: 121
Study 37800367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled interventions (nutrition and parenting)
Number of subjects: 960
Study 37800367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions that engaged fathers
Number of subjects: 960
Study 37800367 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 960
Study 37800372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1538
Study 37800372 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1538
Study 37800374 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to a comprehensive stroke center (CSC) prioritizing endovascular therapy
Number of subjects: 171
Study 37800374 — intervention group
Group type: COMPARATOR
Intervention: Admission to the nearest primary stroke center (PSC) prioritizing intravenous thrombolysis (IVT)
Number of subjects: 171
Study 37800415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent Influenza Vaccine (HD-TIV)
Number of subjects: 170
Study 37800415 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine (SD-QIV)
Number of subjects: 170
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer use
Number of subjects: 909
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic or Latino ethnicity
Number of subjects: 909
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education level lower than a 4-year college degree
Number of subjects: 909
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in North Carolina or Wisconsin (compared to Oregon)
Number of subjects: 909
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing child age (in days)
Number of subjects: 909
Study 37800475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet ownership
Number of subjects: 909
Study 37800546 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient reported outcomes (ePROs)
Number of subjects: 218
Study 37800546 — intervention group
Group type: COMPARATOR
Intervention: Paper patient reported outcomes (pPROs)
Number of subjects: 218
Study 37800559 — intervention group
Group type: EXPERIMENTAL
Intervention: BR (Betamethasone-Ropivacaine) group
Number of subjects: 116
Study 37800559 — intervention group
Group type: COMPARATOR
Intervention: R (Ropivacaine) group
Number of subjects: 116
Study 37800559 — intervention group
Group type: EXPERIMENTAL
Intervention: BR group
Number of subjects: 116
Study 37800559 — intervention group
Group type: COMPARATOR
Intervention: R group
Number of subjects: 116
Study 37800563 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 171
Study 37800563 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 171
Study 37800589 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized risk-based surveillance for pStage II GC patients
Number of subjects: 1661
Study 37800589 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN surveillance guideline for pStage III GC patients
Number of subjects: 1661
Study 37800589 — intervention group
Group type: COMPARATOR
Intervention: pStage III GC patients
Number of subjects: 1661
Study 37800597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivasorexant 100 mg administered twice daily (b.i.d.)
Number of subjects: 0
Study 37800597 — intervention group
Group type: COMPARATOR
Intervention: Cocktail of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4)
Number of subjects: 0
Study 37800633 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist/long-acting β-agonist
Number of subjects: 0